B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MTOR

MOLECULAR TARGET

mechanistic target of rapamycin kinase

UniProt: P42345NCBI Gene: 247527 compounds

MTOR (mechanistic target of rapamycin kinase) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MTOR

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Sirolimus3.8747
2torin 13.2625
3pictilisib2.9418
4Everolimus2.8316
5ly2940022.8316
6Ku 0063794 [Supplementary Concept]2.4811
7Rotenone1.956
8Thapsigargin1.393
9Wortmannin1.393
10alpelisib1.102
11amn0821.102
12Calcimycin1.102
13Idarubicin1.102
14Idazoxan1.102
15Niclosamide1.102
16triolimus [Supplementary Concept]1.102
17tyrphostin 91.102
18egcg0.691
19Ursolic Acid0.691
20Camptothecin0.691
21Dequalinium0.691
22Disulfiram0.691
23Emetine0.691
24Epinephrine0.691
25Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on0.691
26Maprotiline0.691
27Perphenazine0.691

About MTOR as a Drug Target

MTOR (mechanistic target of rapamycin kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented MTOR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MTOR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.